Kornimate/medical-research-clean huggingface dataset:
biological therapy in treating patients with myelodysplastic syndrome

Conditions: Leukemia; Myelodysplastic Syndromes

Summary: rationale: biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. combining different types of biological therapies may kill more cancer cells. purpose: phase ii trial to study the effectiveness of biological therapy in treating patients who have myelodysplastic syndrome.

objectives: * determine the frequency of hematologic responses in patients with myelodysplastic syndrome treated with anti-thymocyte globulin and tumor necrosis factor receptor igg chimera. * correlate phenotypic, cytogenetic, and functional disease characteristics with treatment responses in these patients. * determine the safety of this treatment regimen in this patient population. outline: patients receive anti-thymocyte globulin iv over 8 hours daily for 4 days followed by tumor necrosis factor receptor igg chimera subcutaneously twice weekly for 16 weeks. patients are followed at 8, 16, and 20 weeks. projected accrual: a total of 15 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of myelodysplastic syndrome with no greater than 20% marrow blasts with: * single or multilineage cytopenia (neutrophils less than 2,000/mm\^3 and/or platelet count less than 100,000/mm\^3 and/or reticulocyte count less than 18,000/mm\^3) or * transfusion requirement of at least 2 units packed red blood cells per month and one of the following: * suitable marrow donor unavailable * ineligible for a transplantation protocol * unwilling to proceed with transplantation * no chronic myelomonocytic leukemia patient characteristics: age: * any age performance status: * not specified life expectancy: * not specified hematopoietic: * see disease characteristics hepatic: * not specified renal: * not specified other: * no other severe disease that would preclude study * no active severe infection (e.g., pneumonia or septicemia) or severe infections within the past 2 weeks prior concurrent therapy: biologic therapy: * see disease characteristics * at least 4 weeks since prior hematopoietic growth factors * no concurrent hematopoietic growth factors chemotherapy: * at least 4 weeks since prior cytotoxic therapy * no concurrent cytotoxic therapy endocrine therapy: * not specified radiation therapy: * not specified surgery: * not specified other: * at least 4 weeks since prior immunomodulatory therapy * no concurrent immunomodulatory therapy

Keywords: refractory anemia refractory anemia with ringed sideroblasts refractory anemia with excess blasts refractory anemia with excess blasts in transformation de novo myelodysplastic syndromes previously treated myelodysplastic syndromes secondary myelodysplastic syndromes refractory cytopenia with multilineage dysplasia childhood myelodysplastic syndromes
effect of using irrigations at different temperatures on postoperative period during the extraction of impacted mandibular molars

Conditions: Impacted Third Molar Tooth

Summary: an evaluation of the effect of using irrigations at different temperatures on pain, edema, and trismus during the extraction of bilateral impacted mandibular third molars: a randomized split-mouth clinical trial

abstract introduction: the surgical extraction of impacted wisdom teeth is a standard practice in dentistry. unfortunately, inflammatory reactions such as discomfort, edema, and trismus frequently jeopardize patients' well-being after the extraction of third molars. saline solutions at room temperature (25°c) are routinely used in impacted tooth extraction. refrigerated serums were used to work with cold serum, and since the refrigerator temperature was 4°c, this study was designed to have a cold serum temperature of 4°c. this study aims to assess the influence of saline irrigation at various temperatures (4°c, 25°c) on postoperative edema, pain, and trismus after the extraction of impacted third molars. materials and methods: eighteen patients with bilateral symmetrical mandibular impacted third molars were enrolled in this split-mouth, randomized, prospective, double-blind clinical trial. for each patient, one side was irrigated with a solution at 4°c (test), and the other side was irrigated with a solution at room temperature (25°c) (control). pain, trismus, and facial edema were noted on the 2nd, 4th, and 7th days. a mann-whitney u-test was used to compare pairs, and a wilcoxon signed-rank test was used to compare groups.

Eligibility criteria:
inclusion criteria: * patients aged 18 to 30 who were classified as asa (american society of anesthesiologists)1 and who required the removal of impacted third molars on either the right or left side of the mandible; * presence of impacted mandibular third molars on panoramic radiographs, bilaterally symmetrical, with bone retention and bone removal for extraction, position b class 2 of impacted teeth according to the pell and gregory classification system, and mesioangular position according to the winter classification; * absence of systemic disease and habitual smoking behavior and absence of an allergy to the drugs to be used postoperatively. exclusion criteria: * patients with a history of taking antibiotics and analgesics for at least one month; * having an infection in the operation area and acute pericoronitis or severe periodontal disease before the operation; * the existence of cysts and tumors within proximity of the impacted third molar.

Keywords: irrigation, third molar surgery, temperature,
evaluation of the efficacy and safety of levothyroxine in brain death organ donors: a randomized controled trial

Conditions: Brain Dead Organ Donors

Summary: the primary objective of this study is to evaluate the feasibility of a randomized controlled trial comparing levothyroxine to placebo in neurologically deceased donors


Eligibility criteria:
inclusion criteria: * prior signed written informed from family member (no more needed following amendment in july 2016) * 16 years of age or older * brain death diagnosis * left ventricular ejection fraction \< 50% determined by transthoracic echocardiography or hemodynamic instability defined as a mean dose of noradrenaline 0.1 mcg/kg/min + vasopressin exclusion criteria: * heart failure history (removed after june 2015) * chronic exogenous oral t4 or t3 before death (removed after june 2015) * having received t4 infusion before recruitment(removed after june 2015) * echographic images not interpretable * age 75 and older(removed after june 2015) * prior coronary heart disease defined as prior coronary artery bypass graft or percutaneous coronary intervention (with or without stents)(removed after june 2015)

Keywords: organ donation brain dead levothyroxine
corticosteroid treatment for acute respiratory distress syndrome

Conditions: Acute Respiratory Distress Syndrome

Summary: it is acknowledged that il-18, as a product of the inflammasome, is involved in host defence against viral and bacterial stimuli by modulating the immune response. the aim of this study was to determine il-18 levels in serum of patients with acute respiratory distress syndrome and to investigate whether corticosteroid attenuate its levels. in addition, to explore the effect of corticosteroid therapy on the prognosis of ards.

the acute respiratory distress syndrome (ards) is caused by an inflammatory injury to the lung that is characterized clinically by acute hypoxemic respiratory failure. pathologically complex changes in the lung are manifested by an early, exudative phase followed by proliferative and fibrotic phases. persistent ards is characterized by ongoing inflammation, parenchymal-cell proliferation, and disordered deposition of collagen, all of which may be responsive to corticosteroid therapy. systemic corticosteroids have been considered a potentially beneficial therapy. however, several studies have failed to provide convincing evidence to prove the efficacy of corticosteroids in decreasing the mortality of ards. for the secondary outcomes, such as oxygenation improvement and reduction of the duration of mechanical ventilation, have shown consistent findings in favor of corticosteroid therapy. however, the underlying mechanisms that account for the anti-inflammatory actions of corticosteroid in ards patients have not yet to be elucidated, and the activities do not appear to be controlled by a single mechanism. interleukin-18 (il-18), along with interleukin-1b (il-1b), is produced by inflammasomes when activated by a number of pathogen, environmental or host-derived danger signals. inflammasomes are innate immune regulatory protein complexes which seem to play a key role in the host immune response of patients with ards. the aim of this study is to determine the role of steroid on il-18 levels in serum of patients with ards and its effect on prognosis.

Eligibility criteria:
inclusion criteria: 1. able to provide written informed consent; 2. aged 18-85 years; 3. confirmed diagnosis of ards by berlin criterion exclusion criteria: 1. active tuberculosis and disseminated fungal infection; 2. chronic corticosteroid application 3. patients with organ dysfunction, such as severe liver dysfunction, adrenal insufficiency, severe cardiopulmonary dysfunction; 4. hypogammaglobulinemia or other autoimmune disease; 5. acquired immunodeficiency syndrome; 6. refuse to use corticosteroid; 7. pregnant or nursing

Keywords: corticosteroid acute respiratory distress syndrome
tianjin diabetes and health cohort study

Conditions: Diabetes Mellitus

Summary: the goal of this observational study is to reveal the natural history of diabetes and the occurrence and development patterns of its complications, to evaluate the effectiveness of diabetes interventions, and to assess the health and medical burdens caused by diabetes in tianjin, based on the medical records and health big data in tianjin and correspondingly constructed diabetes-specific cohort.

this study was conducted through the university-enterprise joint laboratory for diabetes epidemiology research at tianjin medical university. retrospective and ongoing medical records and health big data from 396983 diabetes patients treated in secondary and tertiary hospitals in tianjin between 2009 and 2024 were collected to establish a diabetes population cohort. using advanced data mining techniques, multi-dimensional data including electronic health records (ehrs), medical imaging data, and wearable device metrics were analyzed.

Eligibility criteria:
inclusion criteria: * patients diagnosed with diabetes * patients with three or more recorded visits * the following information was complete at the first visit: age, sex, blood glucoseor ,glycated hemoglobin(hba1c) exclusion criteria: * none

Keywords: cohort study diabets complication etiology clinical epidemiology health economic evaluation
use of cemented tfna nail augmentation in the treatment of trochanterian rock fractures

Conditions: the Cement Augmented Screws of TFNA Nails

Summary: intramedullary nailing is the standard treatment of trochanteric fractures. mechanical failure such as cut-out and cut-through are associated with high rates of revision surgery, functional impairment and mortality. augmentation of the implant have shown encouraging results in reducing the number of mechanical failures. the aim of the study was to evaluate the rate of mechanical failure of the cement augmented screws of tfna nails. a descriptive, retrospective, multi-operator, single-centre study was performed at our level 1 trauma centre. patients were included if they were \> 65 years of age, presented with a trochanteric fracture treated with an augmented tfna nail. the primary outcome was fixation failure rate (cut-out or cut-through) at 3 and 6 postoperative months. secondary endpoints were intraoperative data, clinical scores, and radiographic analysis.


Eligibility criteria:
inclusion criteria: * \> 65 years of age * a trochanteric fracture that occurred through a low-energy mechanism * an augmented tfna nail exclusion criteria: * pathological fracture * open fracture * hips with pre-existing deformities other than osteoarthritis * a history of hip surgery * an insufficient quantity of injected cement (\< 3 ml).

Keywords: tfna hip fracture augmentation cement cut-out
phase 1 pilot study of 4-mp to treat stargardt macular dystrophy

Conditions: Macular Dystrophy, Corneal

Summary: the purpose of this study is to investigate whether taking 4-methylpyrazole (4-mp, fomepizole, antizol™) inhibits dark adaptation of the eye. in other words, we are testing if 4-mp slows the processing of vitamin a derivatives in the eye. by slowing down these processes, individuals with stargardt disease may have better chances of saving their remaining vision. 4-mp has been shown to slow dark adaptation in animals, and is fda approved for human use to treat individuals with methanol or ethylene glycol (antifreeze) poisoning by shutting down the body's ability to process alcohols. this medication has an excellent safety profile and has been reported to have no short-term or long-term side effects, as long as patients refrain from any alcohol while the medication is in the body. a single dose of 4-mp remains in the body for about 12 hours, and therefore, it may inhibit dark adaptation of your eyes for up to 12 hours. studying the effects of 4-mp may lead to effective medical treatment to save stargardt patients' vision, and may also have similar effects in other macular degenerative diseases.


Eligibility criteria:
inclusion criteria: * all nonpregnant, nonlactating adults with normal vision in both eyes exclusion criteria: * previous ocular pathologies

Keywords: dark adaptation inhibition stargardt macular dystrophy 4-methylpyrazole (4-mp) antizol fomepizole
high intensity laser and exercises in knee oa

Conditions: Chronic Knee Osteoarthritis

Summary: the purpose of the study is to compare the effect of different doses of energies of high-intensity laser on pain and functional activity in patients with chronic knee oa.

adding hilt to the traditional physical therapy program may reduce pain and improve the functional status of the affected joints. this may provide clinicians with an understanding of the different treatment modalities that may improve the quality of life of patients suffering from chronic knee oa. which may benefit a wide range of individuals affected by this chronic and widespread disease all over the world. although little is known about the efficacy or mechanism of action of what has been termed ''high-intensity laser therapy'' using nd: yag lasers it has become commercially available in veterinary practice and is being marketed for the treatment of musculoskeletal disease. clinical research specific to nd: yag high-intensity laser therapy is required, as it is being used with little supporting evidence. as there was no evidence about the best protocol for the treatment of knee oa as each study was using different doses, different sites of application, different number of phases, frequency of sessions, and the interval between sessions that make it difficult to have the best results. specifically, the dosage range in literature was ranged from 1250 to 3000 j as total energy transmitted during one treatment session. the current study is an attempt to answer the question of which dosage of the energy of high-intensity laser is more effective on pain and functional activities in patients with chronic knee oa at the third degree of osteoarthritis as determined by (kellgren/lawrence grading system) as it was recommended that laser is an ideal treatment for subjects in the later stages of oa .

Eligibility criteria:
inclusion criteria: 1. all subjects diagnosed as third degree chronic knee oa as determined by (kellgren/lawrence grading system) (kellgren and lawrence, 1957). 2. aged between 50- 70 years 3. persistent pain ≥4 on the visual analog scale (vas) for more than 3 months in one or both knees. 4. body mass index (bmi) ≤30 kg/m2. 5. self-reported disability due to knee pain with a score of at least 25 on the western ontario and mcmaster universities osteoarthritis index (womac). 6. all subjects who will participate in this study will read, sign and date an informed consent form which required by ethical committee of faculty of physical therapy, cairo university exclusion criteria: patients will be excluded if they have the following conditions: * history of joint replacement. * symptoms or signs suggestive of another cause of knee pain. * rheumatoid arthritis. * steroid injection or knee surgery (previous six months). * acute inflammation around knee joint. * underlying disease such as malignancy. * infection or systemic disease of musculoskeletal system

Keywords: knee osteoarthritis hilt exercise pain function
does long-term natalizumab (ntz) therapy normalize brain atrophy rates and quality of life (qol) in relapsing remitting multiple sclerosis (rrms)?

Conditions: Multiple Sclerosis

Summary: primary aims: to determine how effective long term natalizumab (ntz) therapy is in slowing the progression of whole brain atrophy. whole brain atrophy rates will be measured through magnetic resonance imaging (mri) scans and compared between patients with multiple sclerosis (ms) who have been using ntz for at least 2 years versus age and gender-matched healthy controls. the primary outcome will be whole brain atrophy rate measured as the percent change in brain volume (pbvc) over a two-year period. primary hypothesis: the investigators hypothesize that long term (\>2 years) ntz therapy will slow the rate of whole brain atrophy in patients with multiple sclerosis (ms) (as measured by percent change in brain volume), reaching a whole brain atrophy rate similar to that of non-ms controls (a true "disease activity free" state).


Eligibility criteria:
inclusion criteria: * 18-55 inclusive years of age at the time of informed consent * diagnosis of relapsing multiple sclerosis as defined by the 2010 revised mcdonald criteria * currently taking tysabri exclusion criteria: * systemic steroid users * comorbidities that could confound mri outcomes
pharmacokinetics, pharmacodynamics and safety of epeleuton in patients with sickle cell disease

Conditions: Sickle Cell Disease

Summary: to assess the pharmacokinetics, pharmacodynamics and safety of epeleuton capsules in adult scd patients who are aged ≥18 years.

the trial will consist of a 28-day screening period, 16 weeks of active treatment and a 30-day post-treatment follow-up period.

Eligibility criteria:
inclusion criteria: * patients with sickle cell disease (scd) including: * 2 sickle hemoglobin genes \[hbss\] * hbsβ0 thalassemia * hbsβ+ thalassemia * heterozygous for hemoglobin s and hemoglobin c \[hbsc\] * male or female patients aged 18 years and older on the day of signing the informed consent form (icf) * patients who have had between 2 and 15 episodes of vaso-occlusive crisis (voc) in the past year (12 months) * for patients taking hydroxyurea (hu), the dose of hu must be stable for at least 3 months prior to signing the icd and with no anticipated need for dose adjustment during the study. * female patients and male patients with female partners of childbearing potential must use highly effective contraceptive methods for the duration of the study. exclusion criteria: * patients who are receiving regularly scheduled blood (rbc) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion), have received an rbc transfusion for any reason within three months of the baseline visit * patients who have received a hematopoietic stem cell transplant. * patients with inadequate venous access as determined by the investigator * patients who are pregnant, planning pregnancy, breastfeeding and/or are unwilling to use adequate contraception during the trial.
the prevalence of radial artery occlusion in diagnostic cardiac catheterization and percutaneous intervention

Conditions: Coronary Angiography; Radial Artery Occlusion

Summary: the purpose of this study is to establish the rate of radial artery occlusion post transradial cardiac catheterization through different modalities. the study hypothesis is that specialized imaging can provide specific information to help identify hand complications after cardiac catheterization through the wrist.

the purpose of this study is to establish the rate of radial artery occlusion post diagnostic/interventional cardiac catheterization through different modalities, and to compare current assessment methods (such as allen's test, modified barbeau test and duplex ultrasonography) to specialized imaging techniques for sensitivity and specificity of radial artery occlusion detection post transradial catheterization. the study hypothesis is that specialized imaging can provide a specific focused analysis of hand characteristics to identify physiologic abnormalities as a result of radial artery occlusion post transradial catheterization.

Eligibility criteria:
inclusion criteria: * adult subjects over the age of 18 who present to the jesse brown va cath lab for a diagnostic radial artery angiogram or percutaneous intervention will be considered for the study. exclusion criteria: * any subject who is unable to give informed consent or declines to participate will be excluded. * patients who have previously had a cardiac catheterization through the radial artery will be excluded because it will not be known if the changes to the circulation of the hand is secondary to the current or previous transradial catheterization.

Keywords: blood flow, regional complications disease, arterial obstructive cardiac catheterization radial artery
real life effectiveness in patients with not optimally controlled asthma

Conditions: Asthma

Summary: a non-interventional study to explore actual asthma control status in real-life environment and to observe the efficacy after stepped-up to symbicort smart or various identical regimens. the study will be implemented by screening asthmatic patients from respiratory clinics to identify those not optimally controlled and required stepping up the controllers to initiate, or to titrate dose of, ics/laba including symbicort.


Eligibility criteria:
inclusion criteria: * asthma patient who was partly controlled or uncontrolled by previous controllers of ics only, or low dose ics plus either laba, leukotriene modifier or theophylline; or ics- naïve with severe and persist symptom based on physician's judgment * according to gina guideline, who need to step up the controller medications, and ics/laba to be prescribed based on physician's discretion exclusion criteria: * patients aged not within limitation refer to label information of various product prescribed * patients who have taken oral corticosteroids within 4 weeks prior to enrollment * patients with contraindications to prescribed medication

Keywords: symbicort smart budesonide formoterol ics/laba asthma control questionnaire not optimally controlled asthma